Bayer's drug sales in Asia-Pac up 8.6% in 2016
PHARMACEUTICAL company Bayer reported an 8.6 per cent increase to 4.8 billion euros (S$7.21 billion) in drug sales in the Asia-Pacific region in 2016.
This is its sixth consecutive year of growth - nearly doubled from 2.6 billion euros in 2010.
Claus Zieler, Bayer's senior vice-president and head of commercial operations at its Asia-Pacific pharmaceutical division, said innovation is the foundation of his company's success.
"Our portfolio of innovative medicines, which addresses the unmet medical needs of patients in the Asia-Pacific region, drives our strong business growth today," he said.
Bayer expects global sales of more than 17 billion euros for its pharmaceuticals division in 2017.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Cordlife substantial shareholder Nanjing Xinjiekou still mulling over offer to buy over remaining shares
Nvidia agrees to acquire Israeli AI software provider Run:ai
HSBC says growing Chinese wealth fuels client investments in US
Unilever's India quarterly profit disappoints
US: Wall St opens higher on tech boost, upbeat earnings
GM CEO Barra compensation fell 4% in 2023 to US$27.8 million